Brown Capital Exits Tandem Diabetes Care Despite $290M Q4 Sales and 15% Growth
Brown Capital’s Small Company Fund sold Tandem Diabetes Care after revenue growth lagged expectations and the company remained unprofitable in 2025. In Q4 2025, Tandem posted $290 million in sales (15% year-over-year) and holds a $1.67 billion market capitalization after missing profit targets.
1. Fund’s Selling Rationale
The Brown Capital Management Small Company Fund fell 1.50% in Q4 2025 and declined 11.46% for the year, trailing the Russell 2000 Growth index. Managers deleted Tandem Diabetes Care from the portfolio after its revenue growth missed expectations and the company remained unprofitable.
2. Q4 Financial Highlights
Tandem reported $290 million in sales during Q4 2025, a 15% increase year-over-year driven by its automated insulin delivery systems. Rising competition and market saturation in insulin pumps undercut revenue momentum and delayed the path to profitability.
3. Implications and Outlook
With a $1.67 billion market capitalization and a 25% share-price decline over the past year, Tandem faces investor pressure to improve margins and accelerate growth. Upcoming product enhancements and partnerships with continuous glucose monitoring providers will be key to regaining confidence and achieving sustainable profitability.